Standard Total Assets from 2010 to 2026

LAB Stock

USD 1.27 0.01 0.78%

Standard Biotools' Total Assets are increasing over the years with slightly volatile fluctuation. Overall, Total Assets are expected to go to about 739.4 M this year. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2007-12-31

Previous Quarter

557 M

Current Value

539.6 M

Quarterly Volatility

172.4 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Standard Biotools financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Standard Biotools' main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.9 M, Interest Expense of 4.4 M or Total Revenue of 210.6 M, as well as many indicators such as Price To Sales Ratio of 4.32, Dividend Yield of 0.0 or PTB Ratio of 1.93. Standard financial statements analysis is a perfect complement when working with Standard Biotools Valuation or Volatility modules.

Build AI portfolio with Standard Stock

Check out the analysis of Standard Biotools Correlation against competitors.

For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.

Latest Standard Biotools' Total Assets Growth Pattern

Below is the plot of the Total Assets of Standard Biotools over the last few years. Total assets refers to the total amount of Standard Biotools assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Standard Biotools books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Standard Biotools' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Standard Biotools' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 612.34 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Standard Total Assets Regression Statistics

	Arithmetic Mean	332,740,234
	Geometric Mean	264,116,268
	Coefficient Of Variation	60.58
	Mean Deviation	144,521,597
	Median	306,395,000
	Standard Deviation	201,575,408
	Sample Variance	40632.6T
	Range	702.9M
	R-Value	0.84
	Mean Square Error	12774T
	R-Squared	0.71
	Significance	0.000025
	Slope	33,523,202
	Total Sum of Squares	650122.3T

Standard Total Assets History

	2026	739.4 M
	2025	704.2 M
	2024	612.3 M
	2023	323.1 M
	2022	390.3 M
	2021	275.2 M
	2020	324.8 M

Other Fundumenentals of Standard Biotools

Intangibles To Total Assets

Standard Biotools Total Assets component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Intangible Assets	Good Will	Long Term Debt	Long Term Debt Total	Capital Surpluse	Cash And Equivalents	Property Plant Equipment	Net Tangible Assets	Net Invested Capital	Capital Stock	Net Working Capital	Short Long Term Debt
Total Assets		0.79	0.87	-0.4	-0.81	0.87	0.96	0.82	0.33	0.93	0.06	0.88	0.29	0.78	-0.69	-0.55	0.64	0.73	0.53	0.75	0.46	-0.07	0.83	0.76
Total Stockholder Equity	0.79		0.58	-0.64	-0.52	0.72	0.85	0.73	-0.31	0.85	-0.26	0.89	0.13	0.78	-0.5	-0.34	0.41	0.44	0.29	0.49	0.85	0.28	0.85	0.67
Current Deferred Revenue	0.87	0.58		-0.35	-0.94	0.91	0.85	0.57	0.46	0.75	0.3	0.76	0.11	0.68	-0.89	-0.82	0.87	0.72	0.74	0.83	0.17	-0.11	0.6	0.71
Net Debt	-0.4	-0.64	-0.35		0.47	-0.53	-0.44	-0.59	0.36	-0.68	-0.08	-0.76	0.65	-0.69	0.57	0.43	-0.48	-0.53	-0.43	-0.63	-0.49	0.0	-0.75	-0.67
Retained Earnings	-0.81	-0.52	-0.94	0.47		-0.88	-0.77	-0.63	-0.46	-0.77	-0.41	-0.77	0.1	-0.66	0.93	0.85	-0.91	-0.8	-0.8	-0.93	-0.09	0.24	-0.63	-0.76
Accounts Payable	0.87	0.72	0.91	-0.53	-0.88		0.9	0.73	0.25	0.84	0.28	0.86	-0.04	0.79	-0.87	-0.76	0.82	0.69	0.8	0.84	0.31	-0.05	0.71	0.8
Net Receivables	0.96	0.85	0.85	-0.44	-0.77	0.9		0.78	0.18	0.89	0.07	0.86	0.26	0.77	-0.71	-0.58	0.64	0.62	0.53	0.71	0.5	0.08	0.77	0.75
Short Term Investments	0.82	0.73	0.57	-0.59	-0.63	0.73	0.78		0.16	0.92	0.14	0.83	-0.01	0.74	-0.57	-0.38	0.45	0.66	0.42	0.74	0.43	-0.16	0.87	0.79
Total Liab	0.33	-0.31	0.46	0.36	-0.46	0.25	0.18	0.16		0.14	0.5	0.0	0.24	0.0	-0.31	-0.32	0.35	0.47	0.37	0.42	-0.58	-0.53	-0.02	0.16
Total Current Assets	0.93	0.85	0.75	-0.68	-0.77	0.84	0.89	0.92	0.14		0.08	0.96	-0.01	0.86	-0.69	-0.5	0.6	0.8	0.52	0.8	0.55	-0.08	0.96	0.86
Short Term Debt	0.06	-0.26	0.3	-0.08	-0.41	0.28	0.07	0.14	0.5	0.08		0.08	-0.38	0.09	-0.47	-0.39	0.39	0.38	0.45	0.47	-0.54	0.02	-0.08	0.49
Common Stock	0.88	0.89	0.76	-0.76	-0.77	0.86	0.86	0.83	0.0	0.96	0.08		-0.1	0.89	-0.74	-0.55	0.65	0.74	0.55	0.79	0.64	0.06	0.95	0.88
Intangible Assets	0.29	0.13	0.11	0.65	0.1	-0.04	0.26	-0.01	0.24	-0.01	-0.38	-0.1		-0.14	0.26	0.25	-0.25	-0.2	-0.34	-0.3	0.19	0.19	-0.08	-0.21
Good Will	0.78	0.78	0.68	-0.69	-0.66	0.79	0.77	0.74	0.0	0.86	0.09	0.89	-0.14		-0.65	-0.51	0.65	0.67	0.59	0.7	0.52	0.04	0.84	0.79
Long Term Debt	-0.69	-0.5	-0.89	0.57	0.93	-0.87	-0.71	-0.57	-0.31	-0.69	-0.47	-0.74	0.26	-0.65		0.95	-0.96	-0.65	-0.83	-0.93	-0.05	0.15	-0.55	-0.74
Long Term Debt Total	-0.55	-0.34	-0.82	0.43	0.85	-0.76	-0.58	-0.38	-0.32	-0.5	-0.39	-0.55	0.25	-0.51	0.95		-0.97	-0.49	-0.83	-0.83	0.1	0.26	-0.35	-0.52
Capital Surpluse	0.64	0.41	0.87	-0.48	-0.91	0.82	0.64	0.45	0.35	0.6	0.39	0.65	-0.25	0.65	-0.96	-0.97		0.64	0.87	0.87	-0.03	-0.26	0.46	0.61
Cash And Equivalents	0.73	0.44	0.72	-0.53	-0.8	0.69	0.62	0.66	0.47	0.8	0.38	0.74	-0.2	0.67	-0.65	-0.49	0.64		0.56	0.8	0.14	-0.29	0.73	0.77
Property Plant Equipment	0.53	0.29	0.74	-0.43	-0.8	0.8	0.53	0.42	0.37	0.52	0.45	0.55	-0.34	0.59	-0.83	-0.83	0.87	0.56		0.78	-0.11	-0.3	0.39	0.55
Net Tangible Assets	0.75	0.49	0.83	-0.63	-0.93	0.84	0.71	0.74	0.42	0.8	0.47	0.79	-0.3	0.7	-0.93	-0.83	0.87	0.8	0.78		0.05	-0.34	0.7	0.81
Net Invested Capital	0.46	0.85	0.17	-0.49	-0.09	0.31	0.5	0.43	-0.58	0.55	-0.54	0.64	0.19	0.52	-0.05	0.1	-0.03	0.14	-0.11	0.05		0.47	0.68	0.39
Capital Stock	-0.07	0.28	-0.11	0.0	0.24	-0.05	0.08	-0.16	-0.53	-0.08	0.02	0.06	0.19	0.04	0.15	0.26	-0.26	-0.29	-0.3	-0.34	0.47		-0.08	0.19
Net Working Capital	0.83	0.85	0.6	-0.75	-0.63	0.71	0.77	0.87	-0.02	0.96	-0.08	0.95	-0.08	0.84	-0.55	-0.35	0.46	0.73	0.39	0.7	0.68	-0.08		0.79
Short Long Term Debt	0.76	0.67	0.71	-0.67	-0.76	0.8	0.75	0.79	0.16	0.86	0.49	0.88	-0.21	0.79	-0.74	-0.52	0.61	0.77	0.55	0.81	0.39	0.19	0.79

Click cells to compare fundamentals

About Standard Biotools Financial Statements

Standard Biotools stakeholders use historical fundamental indicators, such as Standard Biotools' Total Assets, to determine how well the company is positioned to perform in the future. Although Standard Biotools investors may analyze each financial statement separately, they are all interrelated. For example, changes in Standard Biotools' assets and liabilities are reflected in the revenues and expenses on Standard Biotools' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Standard Biotools. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	704.2 M	739.4 M
Intangibles To Total Assets	0.26	0.47

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

JBL	Jabil Circuit
MRK	Merck Company
AMGN	Amgen Inc

When determining whether Standard Biotools offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Standard Biotools' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Standard Biotools Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Standard Biotools Stock:

How To Invest In Standard

Details

Is Standard Stock a good investment?

Details

What is Standard Biotools' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Standard Biotools Correlation against competitors.

For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.

You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.39)

Revenue Per Share

0.448

Quarterly Revenue Growth

(0.14)

Return On Assets

(0.15)

Return On Equity

(0.33)

The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Standard Total Assets from 2010 to 2026

Latest Standard Biotools' Total Assets Growth Pattern

Standard Total Assets Regression Statistics

Standard Total Assets History

Other Fundumenentals of Standard Biotools

Standard Biotools Total Assets component correlations

About Standard Biotools Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY